Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications

Parkinsonism and Related Disorders

Volumn 18, Issue 1, 2012, Pages 40-44

  Drapier, Sophie ^a   Gillioz, Anne Sophie ^b   Leray, Emmanuelle ^b   Péron, Julie ^a   Rouaud, Tiphaine ^a   Marchand, Annaig ^a   Vérin, Marc ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Axial motor symptoms; Neuropsychological assessment; Parkinson's disease; Subcutaneous apomorphine infusion

Indexed keywords

APOMORPHINE; DOMPERIDONE; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTINUOUS INFUSION; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HALLUCINATION; HUMAN; INJECTION SITE NODULE; MALE; MOTOR DYSFUNCTION; NAUSEA; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT SATISFACTION; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SKIN NECROSIS; SUBTHALAMIC NUCLEUS; TREATMENT CONTRAINDICATION; VISUAL ANALOG SCALE;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; DEEP BRAIN STIMULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

EID: 84655169216     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.08.010     Document Type: Article

References (32)

1. Krack P., Batir A., Van Blercom N., Chabardes S., Fraix V., Ardouin C., et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. NEngl J Med 2003, 349(20):1925-1934. Nov 13.
2. Limousin P., Pollak P., Benazzouz A., Hoffmann D., Le Bas J.F., Broussolle E., et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995, 345(8942):91-95. Jan 14.
3. Alegret M., Valldeoriola F., Marti M., Pilleri M., Junque C., Rumia J., et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov Disord 2004, 19(12):1463-1469. Dec.
4. Allert N., Volkmann J., Dotse S., Hefter H., Sturm V., Freund H.J. Effects of bilateral pallidal or subthalamic stimulation on gait in advanced Parkinson's disease. Mov Disord 2001, 16(6):1076-1085. Nov.
5. Drapier D., Drapier S., Sauleau P., Haegelen C., Raoul S., Biseul I., et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?. JNeurol 2006, 253(8):1083-1091. Aug.
6. Funkiewiez A., Ardouin C., Caputo E., Krack P., Fraix V., Klinger H., et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. JNeurol Neurosurg Psychiatry 2004, 75(6):834-839. Jun.
7. Colzi A., Turner K., Lees A.J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. JNeurol Neurosurg Psychiatry 1998, 64(5):573-576. May.
8. Garcia Ruiz P.J., Sesar Ignacio A., Ares Pensado B., Castro Garcia A., Alonso Frech F., Alvarez Lopez M., et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008, 23(8):1130-1136. Jun 15.
9. Manson A.J., Turner K., Lees A.J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002, 17(6):1235-1241. Nov.
10. Pietz K., Hagell P., Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. JNeurol Neurosurg Psychiatry 1998, 65(5):709-716. Nov.
11. De Gaspari D., Siri C., Landi A., Cilia R., Bonetti A., Natuzzi F., et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. JNeurol Neurosurg Psychiatry 2006, 77(4):450-453. Apr.
12. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatry 1992, 55(3):181-184. Mar.
13. Welter M.L., Houeto J.L., Tezenas du Montcel S., Mesnage V., Bonnet A.M., Pillon B., et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002, 125(Pt 3):575-583. Mar.
14. Rouaud T., Dondaine T., Drapier S., Haegelen C., Lallement F., Peron J., et al. Pallidal stimulation in advanced Parkinson's patients with contraindications for subthalamic stimulation. Mov Disord 2010, 25(12):1839-1846. Sep 15.
15. Mattis Dementia Rating Scale Psychological assessment 1988, Ressources Inc, Odessa.
16. Langston J.W., Widner H., Goetz C.G., Brooks D., Fahn S., Freeman T., et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992, 7(1):2-13.
17. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., et al. Arandomized trial of deep-brain stimulation for Parkinson's disease. NEngl J Med 2006, 355(9):896-908. Aug 31.
18. de Boer A.G., van Lanschot J.J., Stalmeier P.F., van Sandick J.W., Hulscher J.B., de Haes J.C., et al. Is a single-item visual analog scale as valid, reliable and responsive as multi-item scales in measuring quality of life?. Qual Life Res 2004, 13(2):311-320. Mar.
19. Stroop J.R. Studies of interferences in serial verbal reactions. JExp Psychol 1935, 18:643-662.
20. Reitan R.M. Validity of the trail making test as an indication of organic brain damage. Percept Mot Skill 1958, 8:271-276.
21. Nelson H.E. Amodified card sorting test sensitive to frontal lobe defects. Cortex 1976, 12(4):313-324. Dec.
22. Cardebat D., Doyon B., Puel M., Goulet P., Joanette Y. Evocation lexicale, formelle et sémantique chez des sujets normaux: performances et dynamiques de production en fonction du sexe, de l'âge et du niveau d'étude. Acta Neurol Belg 1990, 90:207-217.
23. Korczyn A.D., Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 2002, 62(5):775-786.
24. Group P.S. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997, 42(5):747-755. Nov.
25. Di Rosa A.E., Epifanio A., Antonini A., Stocchi F., Martino G., Di Blasi L., et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci 2003, 24(3):174-175. Oct.
26. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005, 20(2):151-157. Feb.
27. Deleu D., Hanssens Y., Northway M.G. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004, 21(11):687-709.
28. van Nuenen B.F., Esselink R.A., Munneke M., Speelman J.D., van Laar T., Bloem B.R. Postoperative gait deterioration after bilateral subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2008, 23(16):2404-2406. Dec 15.
29. Ellis C., Lemmens G., Parkes D., Abbott R.J., Pye I.F., Nigel leigh P., et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 1997, 3(2):103-107. April.
30. Nyholm D., Nilsson Remahl A.I., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64(2):216-223. Jan 25.
31. Antonini A., Isaias I.U., Canesi M., Zibetti M., Mancini F., Manfredi L., et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007, 22(8):1145-1149. Jun 15.
32. Sanchez-Castaneda C., Campdelacreu J., Miro J., Juncadella M., Jauma S., Calopa M. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(1):250-251. Feb 1.